The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective

Journal of Clinical Psychopharmacology

Volumn 18, Issue 2 SUPPL. 1, 1998, Pages

  Lieberman, Jeffrey A ^a   Sheitman, Brian ^a   Chakos, Miranda ^a   Robinson, Delbert ^b   Schooler, Nina ^c   Keith, Sam ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d 7025 Neurosciences Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

CONFERENCE PAPER; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031918239     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199804001-00005     Document Type: Conference Paper

References (18)

1. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997;17:205-29.
2. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76.
3. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
4. McGlashan TH, Fenton WS. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 1993; 19:713-9.
5. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-51.
6. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57[suppl 9]:5-9.
7. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner M. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-63.
8. Lieberman J, Alvir J, Woerner M, Degreef G, Bilder R, Ashtari A, Bogerts B, Mayerhoff D, Loebel A, Levy D, Hinrichsen G, Szymanski S, Chakos M, Borenstein M, Kane J. Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital: design, methodology, and summary of findings. Schizophr Bull 1992;18:351-71.
9. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:660-9.
10. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57[suppl 11]:68-71.
11. Robinson D, Lieberman JA, Sheitman B, Alvir JAJ, Kane J. A pilot study of atypical antipsychotic agents in first episode schizophrenia. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, 1996.
12. Chakos MH, Lieberman JA, Bilder RM, Lerner G, Bogerts B, Degreef G, Wu H, Ashtari M. Increase in caudate nuclei volumes of first episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151:1430-6.
13. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet 1994;344:1434.
14. Chakos MH, Shirakawa O, Lieberman JA, Lee H, Bilder R, Tamminga C. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry (in press).
15. Roberts RC, Gaither LA, Gao XM, Kashyap SM, Tamminga CA. Ultastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 1995;20:234-43.
16. Andreasen OA, Meshul CK, Allen C, Jorgensen HA. Oral dyskinesias and morphological changes in the striatum in rats during long-term haloperidol treatment [abstract]. Soc Neurosci Abstr 1997;23(part 2):2415.
17. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine [letter]. Lancet 1995;345:456-7.
18. Frazier JA, Gied JN, Kaysen D, Albus K, Hamburger S, Alaghband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996;153:564-6.